A RAS inhibitor compound
By forming a ternary complex of chaperone protein and RAS protein within cells and blocking the signaling pathway, the developed RAS inhibitor compound solves the problem of the difficulty in inhibiting RAS-mutant tumors in existing technologies, and achieves effective treatment for multiple RAS mutations.
CN122145451APending Publication Date: 2026-06-05ADLAI NORTYE BIOPHARMA CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ADLAI NORTYE BIOPHARMA CO LTD
- Filing Date
- 2025-12-03
- Publication Date
- 2026-06-05
AI Technical Summary
Technical Problem
Existing technologies are insufficient to effectively inhibit tumors caused by RAS mutations, especially other RAS mutations besides KRASG12C mutations, and there is a lack of satisfactory inhibitory compounds.
Method used
By mediating the formation of a ternary complex between a ubiquitous intracellular chaperone protein and the RAS protein, blocking the binding of RAS to downstream effector molecules, and inhibiting the MAPK and PI3K-AKT signaling pathways, a RAS inhibitor compound with a specific structure was developed.
Benefits of technology
It effectively inhibits the occurrence and development of tumors caused by RAS mutations, provides treatment options for multiple RAS mutations, and breaks the limitation that RAS is considered untreatable.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122145451A_ABST
Abstract
The present application relates to a RAS inhibitor compound having a structure represented by Formula (A), an isotopic derivative, a stereoisomer, or a pharmaceutically acceptable salt thereof, and uses thereof in the prevention and / or treatment of cancer, a tumor, an inflammatory disease, an autoimmune disease, or an immune-mediated disease.
Need to check novelty before this filing date? Find Prior Art